We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Societal CDMO Inc (SCTL) USD0.01

Sell:$1.08 Buy:$1.10 Change: $0.01 (0.92%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Tender Offer

Societal CDMO Inc USD0.01

Type:
Tender Offer
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 26 Mar 2024)

Cane Merger Sub Inc, a wholly owned subsidiary of CoreRx Inc, has made an offer to buy Societal CDMO Inc shares at a price of USD1.10 per share as part of a merger offer.

 

If you don’t want to sell any shares, you don’t need to do anything. Depending on the level of acceptance the offeror intends to compulsorily acquire the remaining shares at a later date.

 

Accept the offer – Act by noon on Tuesday 2 April 2024

 

Cash from any successful tender will be converted from US Dollars to Pound Sterling upon receipt, based on the prevailing exchange rate at the time and our standard currency conversion fees and credited to your account.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above.

×
Sell:$1.08
Buy:$1.10
Change: $0.01 (0.92%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Tender Offer

Societal CDMO Inc USD0.01

Type:
Tender Offer
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 26 Mar 2024)

Cane Merger Sub Inc, a wholly owned subsidiary of CoreRx Inc, has made an offer to buy Societal CDMO Inc shares at a price of USD1.10 per share as part of a merger offer.

 

If you don’t want to sell any shares, you don’t need to do anything. Depending on the level of acceptance the offeror intends to compulsorily acquire the remaining shares at a later date.

 

Accept the offer – Act by noon on Tuesday 2 April 2024

 

Cash from any successful tender will be converted from US Dollars to Pound Sterling upon receipt, based on the prevailing exchange rate at the time and our standard currency conversion fees and credited to your account.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above.

×
Sell:$1.08
Buy:$1.10
Change: $0.01 (0.92%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Tender Offer

Societal CDMO Inc USD0.01

Type:
Tender Offer
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 26 Mar 2024)

Cane Merger Sub Inc, a wholly owned subsidiary of CoreRx Inc, has made an offer to buy Societal CDMO Inc shares at a price of USD1.10 per share as part of a merger offer.

 

If you don’t want to sell any shares, you don’t need to do anything. Depending on the level of acceptance the offeror intends to compulsorily acquire the remaining shares at a later date.

 

Accept the offer – Act by noon on Tuesday 2 April 2024

 

Cash from any successful tender will be converted from US Dollars to Pound Sterling upon receipt, based on the prevailing exchange rate at the time and our standard currency conversion fees and credited to your account.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above.

×
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization (CDMO). The Company is engaged in spanning pre-investigational new drug development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a primary focus on the area of small molecules. It is involved in CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company’s products include Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR, Donnatal liquids and tablets and Scot-Tussin cough and cold liquids. Its manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms and facilities to handle highly potent compounds and controlled substances.

Contact details

Address:
1 E. UWCHLAN AVE, SUITE 112
EXTON
19341
United States
Telephone:
+1 (770) 5348239
Website:
https://www.societalcdmo.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SCTL
ISIN:
US75629F1093
Market cap:
$115.20 million
Shares in issue:
105.69 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Wayne Weisman
    Executive Chairman of the Board
  • J. David Enloe
    President, Chief Executive Officer, Director
  • Ryan Lake
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.